ABT - Company ID 0000001800
ABBOTT LABORATORIES trades as ABT and has a market capitalization of $163.95 B, making it the #97 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $44.33B, up 5.7% from the prior year and net income of $6.52B. This page tracks ABBOTT LABORATORIES through 1,001 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ABBOTT LABORATORIES's revenue grew from $20.85B to $44.33B, a compound annual growth rate of 8.7%. Net profit margin expanded from 6.7% to 14.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G | - | 2026-04-29 |
| Insider trade | 4 | 2026-04-29 |
| Quarterly report | 10-Q | 2026-04-29 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
Archive of Abbott investor newsletters, highlighting the latest in Abbott updates for the savvy investor.
Sales for the quarter totaled $11.2 billion, a 3.7% increase on a comparable basis1 (7.8% reported), with growth led by Medical Devices and ...
Abbott reported first-quarter 2025 results, delivering top-tier sales and EPS growth. The company's diversified business model is helping it ...
Reported sales decreased 8.1% due to the anticipated decline in COVID-19 testing-related revenue. Full-year adjusted diluted EPS was $4.44, ...
Abbott reported second-quarter 2025 results, with steady performance across multiple key business segments. Halfway through 2025, we are on ...
The largest companies sharing ABBOTT LABORATORIES's SEC industry classification (pharmaceutical preparations).
ABBOTT LABORATORIES (ABT) has a market capitalization of $163.95 B as of 2026-07-09, ranking #97 among US-listed companies.
ABBOTT LABORATORIES reported revenue of $44.33B for fiscal year 2025, an increase of 5.7% year over year.
Yes. ABBOTT LABORATORIES reported net income of $6.52B in its latest fiscal year.